Latest Research in Hematologic Oncology and Apoptotic Signaling

Top Research Topics in Hematologic Oncology and Apoptotic Signaling

• Acute Myeloid Leukemia Research — 11 papers
• Philosophical Ethics and Theory — 2 papers
• Adversarial Robustness in Machine Learning — 1 papers
• Cell death mechanisms and regulation — 1 papers

Highest-Cited Papers

1. Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (1 citations)
2. Can Offline-Optimized Latent Adversarial Perturbations Be Amortized? A Study of Teacher–Student Distillation for Real-Time Speech Protection
3. Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
4. Wired to Survive: How AML Cytogenetics Shape Apoptotic Dependence and Venetoclax Resistance
5. CD84 expression stratifies venetoclax response and reveals a targetable vulnerability in resistant acute myeloid leukemia
6. Comparison of venetoclax and azacitidine versus a cytarabine‐based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real‐world study of the DATAML ‐ IPC ‐ AURAML consortium
7. The Constituent Logic of Being: Identity, Non-Contradiction, Determinacy, and Rendering
8. The Constituent Logic of Being: Identity, Non-Contradiction, Determinacy, and Rendering
9. Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients
10. Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study
11. Retrospective evaluation of venetoclax-based regimen in newly diagnosed and relapsed/refractory acute myeloid leukemia: Efficacy determinants, survival outcomes, and model validation
12. Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies
13. The introduction of hypomethylation agents and venetoclax into standard care for older patients with acute myeloid leukemia: A retrospective real-world analysis of feasibility, safety, and effectiveness from an outpatient hematology center.
14. Modified azacitidine plus cytarabine versus traditional cytarabine in patients with newly diagnosed acute myeloid leukaemia: a retrospective and propensity score matched analysis
15. Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents

Sub-Regions

• Acute Myeloid Leukemia Research — 12 papers
• Medical, Sociocultural, and Biopolitical Studies — 8 papers
• Philosophical Ethics and Theory — 2 papers